Arcoma AB (ARCOMA) Fair Value & Analysis
Healthcare · SE · Market cap 120M SEK
Fair value as of: Jun 24, 2026
Analysis
Arcoma AB (ARCOMA) currently trades at kr 8.50, while our model-based Fair Value estimate is kr 10.36 — implying the stock looks roughly 21.9% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Arcoma AB develops, produces, and provides radiology solutions and digital x-ray systems in Sweden and internationally. The company offers solutions for x-ray systems covering radiological applications and general, eneral, muscle/skeleton, thoratic, pediatric, and trauma/resus clinics. It also provides x-ray detectors; video bank; and accessories for x-ray equipment comprising live camera, advanced remote control, form pad, hand control, compression belt, lateral cassette/detector holder, foot control, lateral armrest, patient handgrip, mattress, scatter correction software, battery charger, battery pack, and stitching screen. It manufactures x-ray equipment under the Canon and Konica Minolta brand name. The company sells its products through resellers and OEM customers. Arcoma AB was incorporated in 1990 and is based in Växjö, Sweden.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Arcoma AB (ARCOMA) undervalued?
What is the fair value of ARCOMA?
What is the quality score of ARCOMA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.